|
|||||
|
|
Verapamil in the prophylaxis of bronchial asthma |
|
| Authors: | E. Imhof S. Elsasser B. Rosmus H. R. Ha F. Follath A. P. Perruchoud |
| Affiliation: | (1) Division of Respiratory Diseases, Department of Internal Medicine and Department of Research, University Hospital Basel, Basel, Switzerland;(2) Division of Clinical Pharmacology, Department of Internal Medicine and Department of Research, University Hospital Base, Basel, Switzerland |
| Abstract: | Summary A single oral dose of verapamil 80 mg was shown significantly to inhibit histamine-induced bronchoconstriction in 8 out of 16 asthmatic subjects (maximum increase in PD20FEVHi 416%). There was still significant protection ( PD20FEV1Hi>100%) in the responders 5 h after the oral dose. The relationship of the bronchoprotective effect to the plasma level of verapamil was also examined. Responders and non-responders did not differ significantly in the peak plasma level or the time course of the plasma verapamil concentration.The protective effect was not correlated with the peak plasma level of verapamil or with the baseline bronchial hyperreactivity. |
| Keywords: | Asthma Verapamil histamine-induced bronchoconstriction calcium antagonists plasma levels pharmacokinetics |
| 本文献已被 SpringerLink 等数据库收录！ | |